Browsing by Author "Mogulkoc N."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients
    (Elsevier Ireland Ltd, 2008) Ozkok S.; Karakoyun-Celik O.; Goksel T.; Mogulkoc N.; Yalman D.; Gok G.; Bolukbasi Y.
    The aim of this study was to evaluate the symptomatic and endoscopic responses as well as the toxicities in 158 patients with endobronchial lung cancer treated with high dose rate endobronchial brachytherapy (HDR-EB). Forty-three patients with stage III NSCLC were treated with 60 Gy external beam radiotherapy (ERT) and three applications of 5 Gy each of HDR-EB (group A). Seventy-four patients who did not receive previous RT were treated with 30 Gy ERT and two applications of 7.5 Gy HDR-EB with palliative intent (group B). Forty-one patients with recurrent tumor who were irradiated previously were treated with three applications of 7.5 Gy HDR-EB, with palliative intent (group C). In group A, bronchoscopic complete (CR) and overall response rates (ORR) were 67% and 86%, respectively. Symptomatic improvement was obtained in 58% of patients with cough, 77% of patients with dyspnea and 100% of patients with hemoptysis. Two and 5-year survival rates were 25.5% and 9.5%, respectively and the median survival time (MST) was 11 months. In group B, the bronchoscopic CR and ORR were 39% and 77%, respectively and 28% and 72% in group C. The symptomatic response rates were 57% and 55% for cough, 90% and 78% for dyspnea and 94% and 77% for hemoptysis, with a MST of 7 and 6 months in Groups B and C, respectively. Eighteen patients (11%) died of fatal hemoptysis (FH) with the median time to this event of 7 months. Treatment intent (p < 0.001), total BED (p < 0.001) and the number of HDR-EB fractions (p < 0.001) were significant prognostic factors for FH. HDR-EB provides effective palliation in relieving the symptoms of patients with endobronchial lung cancer, however, there is a risk of developing FH that is associated with a high BED and multiple HDR-EB applications. © 2008 Elsevier Ireland Ltd. All rights reserved.
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    Childhood interstitial lung disease survivors in adulthood: a European collaborative study
    (2025) Manali E.D.; Griese M.; Nathan N.; Uzunhan Y.; Borie R.; Michel K.; Schwerk N.; Fijolek J.; Radzikowska E.; Chua F.; Pabary R.; Mogulkoc N.; McCarthy C.; Kallieri M.; Papaioannou A.I.; Kiper N.; Koziar Vasakova M.; Lacina L.; Molina-Molina M.; Torrent-Vernetta A.; Tsiligiannis T.; Karadag B.; Kokosi M.; Renzoni E.A.; van Moorsel C.H.M.; Campo I.; Bendstrup E.; Prior T.S.; Prasse A.; Bonella F.; Cottin V.; Diesler R.; Froidure A.; Kolilekas L.; Fotis L.; Douros K.; Kaditis A.G.; Jeny F.; Chauveau S.; Nunes H.; Dahbia A.; Mariani F.; van der Vis J.J.; Groen K.; Erdem Eralp E.; Gokdemir Y.; Kocakaya D.; Olgun Yildizeli S.; Yalçın E.; Emiralioğlu N.; Nayir Buyuksahin H.; O'Brien H.; Karcıoglu O.; Can D.; Ezircan A.; Kartal Ozturk G.; Ocal N.; Yuksel H.; Narin Tongal S.; Safrankova M.; Kourtesi K.; Louvrier C.; Kannengiesser C.; Fabre A.; Legendre M.; Crestani B.; Pohunek P.; Bush A.; Papiris S.A.
    BACKGROUND: Interstitial lung disease is rarer in children than adults, but, with increasing diagnostic awareness, more cases are being discovered. The prognosis of childhood interstitial lung disease is often poor, but increasing numbers are now surviving into adulthood. AIM: To characterise childhood interstitial lung disease survivors and identify their impact on adult interstitial lung disease centres. METHODS: This was a European study (34 adult and childhood interstitial lung disease centres) reporting incident/prevalent cases of childhood interstitial lung disease survivors from January to July 2023. Epidemiological, clinical, physiological and genetic data were collected. RESULTS: 244 patients were identified with a median (interquartile range) age at diagnosis of 12.5 years (6-16 years) and age at study inclusion of 25 years (22-33 years), with 51% male, 86% nonsmokers and a median (interquartile range) % predicted forced vital capacity of 70% (47-89%) and diffusing capacity of the lungs for carbon monoxide of 48% (32-75%). 32% were prescribed long-term oxygen and 227 (93%) were followed up in adult centres whereas 17 (7%) never transitioned. The commonest diagnoses (82%) were childhood interstitial lung disease category B1 (sarcoidosis, hemosiderosis, connective tissue disorders, vasculitis) at 35%, A4 (surfactant-related) at 21%, B2 (bronchiolitis obliterans, hypersensitivity pneumonitis) at 14% and Bz (unclassified interstitial lung disease) at 13%. Bz patients had the worst functional status. 60% of all patients were still being prescribed corticosteroids. Re-specification of diagnosis and treatment were made after transition for 9.8% and 16% of patients, respectively. Not all childhood interstitial lung disease diagnoses were recognised in adult interstitial lung disease classifications. CONCLUSION: Childhood interstitial lung disease survivors are seen in most adult interstitial lung disease centres and only a minority continue follow-up in paediatric centres. Survivors have a significant loss of lung function. The heterogeneity of their aetiologies and therapeutic requirements has a real impact on adult interstitial lung disease centres. Re-specification of diagnosis and treatment may contribute to precision and personalisation of management. Copyright ©The authors 2025. For reproduction rights and permissions contact permissions@ersnet.org.